Zacks Investment Research lowered shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a buy rating to a hold rating in a research report report published on Monday morning.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
Separately, ValuEngine downgraded AEterna Zentaris from a hold rating to a sell rating in a research report on Friday, August 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $3.25.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The firm had revenue of $0.66 million for the quarter. AEterna Zentaris had a return on equity of 83.33% and a net margin of 34.40%. On average, analysts forecast that AEterna Zentaris will post 0.05 earnings per share for the current year.
A hedge fund recently bought a new stake in AEterna Zentaris stock. Virtu Financial LLC bought a new position in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 51,028 shares of the biopharmaceutical company’s stock, valued at approximately $101,000. Virtu Financial LLC owned 0.31% of AEterna Zentaris at the end of the most recent quarter. 2.95% of the stock is currently owned by institutional investors and hedge funds.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.